CGTX News and Press, Cognition Therapeutics Inc. From 04/04/22

Gainers: Protalix BioTherapeutics (PLX) +74%. Aterian (ATER) +62%. Dingdong Limited (DDL) +40%. Jumia Technologies (JMIA) +30%. Twitter (TWTR) +27%. Takung Art (TKAT) +24%. Gracell Biotechnologies (GRCL) +22%. Cognition Therapeutics (CGTX) +21%. Poema Global Holdings (PPGH) +20%. Biophytis (B...

Cognition Therapeutics, Inc. (CGTX) Q4 2021 Earnings Call March 30, 2022 08:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Jim O'Brien - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R...

Cognition Therapeutics press release (NASDAQ:CGTX): FY GAAP EPS of -$3.13 misses by $2.64. Cash and cash equivalents on December 31, 2021 was $54.7 million. For further details see: Cognition Therapeutics GAAP EPS of -$3.13 misses by $2.64

- Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program - - Conference call and live audio webcast scheduled for Wednesday, March 30 at 8:00 a.m. ET -...

PURCHASE, N.Y., March 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the...

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) , a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results fr...

PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that the Company’s president...

PURCHASE, N.Y., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that Anthony Caggiano, M.D., Ph.D. , chief medical officer and ...

Point Roberts, WA and Delta, BC - January 14, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Mining, Plant-Based and Tech. Today's stocks have been added to our lists o...

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the ...